Abstract Activation of CD8 +T cells against pathogens and cancers involves the recognition antigenic peptides presented in complex with human leukocyte antigen (HLA) class-I proteins. Peptide binding to HLA-I proteins is coordinated by a multi-protein called peptide loading (PLC). Tapasin, key PLC component, facilitates optimization peptides. However, different allotypes have variable requireme...

Recently, we have shown that HLA-A*02:01 and HLA-A*24:02 in de novo metastatic prostate cancer (MPCa) an important role disease progression. Since MPCa represents a small group among patients diagnosed with (PCa), it was obvious to try extend the validity of our results larger cohorts PCa patients. Herein, analyzed irrespective their status at diagnosis include, besides MPCa, those localized (L...

conclusions our investigation demonstrated that there is a highly significant association between the studied alleles and t1d. it can be construed that haplotype hla-dr3-dq2 has a very modest effect with respect to the risk of t1d. patients and methods this study was a case-control study. the number of samples was determined using the cochran formula. eighty unrelated t1d patients, including 42...

background: hla-g gene contains 15 alleles including a null allele, hla-g*0105n. previous studies have shown that hla-g*0105n does not encode the complete hla-g1 or hla-g5 isoforms but encodes a functional hla-g protein with the ability to in-hibit nk cell cytolysis. thus, although the biological functions of hla-g1 and hla-g5 proteins are abrogated, other isoforms such as hla-g2 can replace th...

Severe cutaneous adverse drug reaction (SCAR) is considered to be a multifactorial drug side effect. This study was designed to investigate the epidemiology and human leukocyte antigen (HLA)-A and -B gene polymorphisms in pediatric patients with SCAR admitted in tertiary referral center, southwestern of Iran from 2013 to 2017. Demographic data, past allergy and autoimmune history, clinical pres...

Letetresgene autoleucel is a genetically engineered NY-ESO-1–specific TCR T-cell therapy being investigated in mSS patients whose tumours express the NY-ESO-1 antigen and who are HLA-A*02:01, HLA-A*02:05, or HLA-A*02:06 allele positive (NY+/HLA+). Our objective was to understand prevalence & clinical characteristics of NY+/HLA+ nationally representative population. This retrospective cohort stu...